Atreca, Inc. (BCEL)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:36PM EDT
| Previous close | 0.0880 |
| Open | 0.0880 |
| Bid | 0.1830 x 1000 |
| Ask | 0.1900 x 900 |
| Day's range | 0.0880 - 0.0953 |
| 52-week range | 0.0520 - 1.2640 |
| Volume | |
| Avg. volume | 577,955 |
| Market cap | 3.529M |
| Beta (5Y monthly) | 1.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
- Simply Wall St.
We're A Little Worried About Atreca's (NASDAQ:BCEL) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
© 2024 Yahoo. All rights reserved.